Research Progress of Duodenal-Jejunal Bypass Liner in the Treatment of Obesity and Type 2 Diabetes Mellitus

Figures & data

Figure 1 The duodenal-jejunal bypass liner (left)—and in situ (right) (Supported by Tongee Medical Technology Co. Ltd).

Table 1 Clinical Efficacy of DJBL: Prospective, Open-Label Trial

Study	Number of Cases (T2DM in Brackets)	Pre-DJBL BMI (kg/m^2)	Baseline HbA1c	Study Duration (Weeks)	Post-DJBL EWL (%)	Post-DJBL Weight Loss (kg)	Post-DJBL HbA1c	Post-DJBL Fasting Blood Glucose
Leonardo Rodriguez-Grunert et al 2008^Citation6	12(4)	43	-	12	23.6	-	HbA1c decreased in 3 patients (< 5%)	Four patients returned to normal fasting blood glucose
Eduardo G.H et al 2012^Citation7	22(22)	44.8±7.4	8.9%±1.7%	52	39.0±3.9	-	Down by 2.1%±0.3%	Down by 30.3±10.2 mg/dL
Charlotte de Jonge et al 2013^Citation8	17(17)	30–50	8.4%±0.2%	24	-	12.7±1.3	7.0%±0.2%	Down by 3.0mmol/L
Bark Betzel et al 2017^Citation9	185(185)	35.1±4.3	67 mmol/mol	46±15	46±18	12.8±8.0	61 mmol/mol	-
Liat Deutsch et al 2018^Citation10	39(39)	37.5±5.0	7.2%	39	15.1%±6.0%(TBWL%)	18.6	6.3%	-

Abbreviations: BMI, body mass index; EWL, excess weight loss; TBWL, total body weight loss; HbA1c, hemoglobin A1c; -, not listed.

Table 2 Clinical Efficacy of DJBL: Randomized Controlled Trial

Study	Number of Cases	Pre-DJBL BMI (kg/m^2)	Pre-DJBL HbA1c	Study Duration (Weeks)	Body Weight Change (kg)	BMI Decrease (kg/m^2)	Post-DJBL EWL (%)	Post-DJBL HbA1c
M. Tarnoff et al 2009^Citation11	25(versus 14 diet control)	42.0±5.1 device 40.0±3.5 in control	-	12	10.3±3.2 device 2.6±3.5 in control	-	22.0% device 5.0% in control	-
Keith S. Gersin et al 2010^Citation12	13(versus 24 sham control)	46.0 device 46.0 in control	-	12	8.2±1.3 device 2.1±1.1 in control	-	11.9%±1.4% device 2.7%±2.0% in control	-
Ruben Schouten et al 2010^Citation13	26(versus 11 diet control)	48.9 device 47.4 in control	8.8% device 7.3% in control	13	-	5.5 device 1.9 in control	19.0% device; 6.9% in control	7.7% device 6.9% in control
Parviez Koehestanie et al 2014^Citation14	34(versus 39 diet control)	34.6 device; 36.8 in control	8.3% device 8.3% in control	26	10.6 device; 5.3 in control	3.3 device 1.8 in control	32.0% device; 16.4% in control	7.0% device 7.9% in control

Abbreviations: BMI, body mass index; EWL, excess weight loss; HbA1c, hemoglobin A1c; -, not listed.

Rodriguez-Grunert L, Galvao Neto MP, Alamo M, Ramos AC, Baez PB, Tarnoff M. First human experience with endoscopically delivered and retrieved duodenal-jejunal bypass sleeve. Surg Obes Relat Dis. 2008;4(1):55–59. doi:10.1016/j.soard.2007.07.012

 PubMed Web of Science ®Google Scholar

de Moura EG, Martins BC, Lopes GS, et al. Metabolic improvements in obese type 2 diabetes subjects implanted for 1 year with an endoscopically deployed duodenal-jejunal bypass liner. Diabetes Technol Ther. 2012;14(2):183–189. doi:10.1089/dia.2011.0152

 PubMed Web of Science ®Google Scholar

de Jonge C, Rensen SS, Verdam FJ, et al. Endoscopic duodenal-jejunal bypass liner rapidly improves type 2 diabetes. Obes Surg. 2013;23(9):1354–1360. doi:10.1007/s11695-013-0921-3

 PubMed Web of Science ®Google Scholar

Betzel B, Homan J, Aarts EO, et al. Weight reduction and improvement in diabetes by the duodenal-jejunal bypass liner: a 198 patient cohort study. Surg Endosc. 2017;31(7):2881–2891. doi:10.1007/s00464-016-5299-6

 Web of Science ®Google Scholar

Deutsch L, Ben Haim L, Sofer Y, Gluck N, Santo E, Fishman S. Long-term effects of proximal small bowel exclusion by duodenal-jejunal bypass liner on weight reduction and glycemic control in diabetic patients. Surg Obes Relat Dis. 2018;14(10):1561–1569. doi:10.1016/j.soard.2018.07.022

 Web of Science ®Google Scholar

Tarnoff M, Rodriguez L, Escalona A, et al. Open label, prospective, randomized controlled trial of an endoscopic duodenal-jejunal bypass sleeve versus low calorie diet for pre-operative weight loss in bariatric surgery. Surg Endosc. 2009;23(3):650–656. doi:10.1007/s00464-008-0125-4

 Web of Science ®Google Scholar

Gersin KS, Rothstein RI, Rosenthal RJ, et al. Open-label, sham-controlled trial of an endoscopic duodenojejunal bypass liner for preoperative weight loss in bariatric surgery candidates. Gastrointest Endosc. 2010;71(6):976–982. doi:10.1016/j.gie.2009.11.051

 PubMed Web of Science ®Google Scholar

Schouten R, Rijs CS, Bouvy ND, et al. A multicenter, randomized efficacy study of the EndoBarrier Gastrointestinal Liner for presurgical weight loss prior to bariatric surgery. Ann Surg. 2010;251(2):236–243. doi:10.1097/SLA.0b013e3181bdfbff

 PubMed Web of Science ®Google Scholar

Koehestanie P, de Jonge C, Berends FJ, Janssen IM, Bouvy ND, Greve JW. The effect of the endoscopic duodenal-jejunal bypass liner on obesity and type 2 diabetes mellitus, a multicenter randomized controlled trial. Ann Surg. 2014;260(6):984–992. doi:10.1097/SLA.0000000000000794

 PubMed Web of Science ®Google Scholar